HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering
Journal for ImmunoTherapy of Cancer · 2026-03 · 14 (3) · e014185
DOI: 10.1136/jitc-2025-014185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 30.03.2026. Verfasst von Jiliang Zhao und 32 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and Frontiers Science Center for Cell Responses, Academy for Advanced In…. Hauptthemen laut MEDLINE: Receptors, OX40, T-Lymphocytes, Regulatory, Immunotherapy, T-Lymphocytes, Cytotoxic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Tianjin Municipal Major Science and Technology Special Projects and Engineering -National Key Laboratory Major Projects, Tianjin Science and Technology Major Project.
Abstract (Originalsprache)
Background
OX40, a key co-stimulatory receptor that amplifies T cell-mediated anti-tumor immunity, is a promising immunotherapeutic target. Despite most reported OX40 agonists in clinical trials having high affinity, the relationship between affinity and agonistic activity remains complex, necessitating further clarification of affinity’s impact on OX40-based immunotherapy efficacy and its underlying mechanisms.
Methods
We generated the different affinity OX40 agonist antibodies were generated by phage display. Antibody-receptor interactions were modeled using AI-based prediction and validated by hydrogen-deuterium exchange. We assessed the receptor clustering, T cell activation, and regulatory T cell (Treg) depletion effect of OX40 antibodies with different affinities by confocal microscopy and reporter cell assays. We further evaluated the anti-tumor efficacy in multiple murine tumor models. The effects of HFB301001 treatment on tumor-infiltrating T cells, safety in cynomolgus monkeys, and immune activation in clinical samples were investigated using single-cell RNA sequencing (scRNA-seq), flow cytometry, ELISpot, and immunofluorescence.
Results
We identified the low-affinity OX40 agonist antibody HFB301001 and generated variants with different affinities via phage display. Compared with its high-affinity mutant, HFB301001 induced stronger receptor clustering, enhanced T cell activation, and mediated more potent natural killer-mediated antibody-dependent cell-mediated cytotoxicity for Treg depletion than its high-affinity mutant in vitro. Consistently, HFB301001 outperformed the high-affinity mutant by boosting intratumoral T cell infiltration/activation and Treg clearance in vivo. Additionally, HFB301001 exhibited favorable safety in cynomolgus monkeys and effectively activated tumor-infiltrating T cells in a clinically relevant tumor slice culture system.
Conclusions
The reduced-affinity strategy represents a promising framework for the clinical development of OX40-targeted cancer immunotherapies. Currently, HFB301001 is concluding in a phase I clinical study involving patients with advanced solid tumors ( NCT05229601 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and Frontiers Science Center for Cell Responses, Academy for Advanced Interdisciplinary Studies, Nankai University, Tianjin, China.
- HiFiBiO Therapeutics, Cambridge, Massachusetts, USA.
- Central Laboratory, Affiliated Hospital of Changzhi Medical College, Changzhi People's Hospital, Changzhi, Shanxi, China.
- NITFID, School of Statistics and Data Science, AAIS, LPMC and KLMDASR, Nankai University, Tianjin, China.
- Department of Lung Cancer Surgery, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, Tianjin, China.
- Institute of Transplantation Medicine, Nankai University, Tianjin First Central Hospital, Tianjin, China.
Förderung
- National Natural Science Foundation of China
- Tianjin Municipal Major Science and Technology Special Projects and Engineering -National Key Laboratory Major Projects
- Tianjin Science and Technology Major Project
- Tianjin Science and Technology Plan Project
Zitieren
APA
Zhao, J., Zhang, D., Lu, Y. Y., Jin, R., Li, F., Zhang, Z., Ni, W., Gong, N., Wang, Y., Yin, Z., Du, Y., Ma, W., Wang, X., Zu, L., Liu, S., Yang, K., Bai, Y., Gan, J., Adrian, F., …, & Zhang, H. (2026). HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering. Journal for ImmunoTherapy of Cancer, 14(3), e014185. https://doi.org/10.1136/jitc-2025-014185
Vancouver
Zhao J, Zhang D, Lu YY, Jin R, Li F, Zhang Z, et al. HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering. Journal for ImmunoTherapy of Cancer. 2026;14(3):e014185. doi:10.1136/jitc-2025-014185
BibTeX
@article{Zhao2026,
author = {Zhao, Jiliang and Zhang, Dongping and Lu, Yun-Yueh and Jin, Ruina and Li, Fan and Zhang, Zhaoyuan and Ni, Wentao and Gong, Nanxin and Wang, Yi and Yin, Zhongqian and Du, Yazhuo and Ma, Wenxuan and Wang, Xiaoqian and Zu, Lingling and Liu, Shiyu and Yang, Kailu and Bai, Yiyang and Gan, Jinping and Adrian, Francisco and Hong, Zhangyong and Zhang, Sihe and Chang, Yunsong and Wang, Zhenyu and Jin, Xin and Zhong, Jianguo and Ge, Kunkun and Peng, Sibo and Ding, Dan and Zheng, Wei and Xu, Song and Wang, Wei and Schweizer, Liang and Zhang, Hongkai},
title = {HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {3},
pages = {e014185},
doi = {10.1136/jitc-2025-014185}
}
EUVIMED